COMMUNIQUÉS West-GlobeNewswire

Nyxoah to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

03/03/2025 - 22:30

Nyxoah to Participate in the Oppenheimer 35 th Annual Healthcare MedTech & Services Conference Mont-Saint-Guibert, Belgium – March 3, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“ [...]

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March

03/03/2025 - 22:30

TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor [...]

ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe

03/03/2025 - 22:30

PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) approval of Purified Cortrophin® Gel (repository [...]

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03/03/2025 - 22:30

MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life [...]

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences

03/03/2025 - 22:35

Company to Host Conference Call on March 20 at 8:30 a.m. ET SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients [...]

23andMe Special Committee Rejects Acquisition Proposal From CEO Anne Wojcicki

03/03/2025 - 22:35

SUNNYVALE, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME) today confirmed receipt of a non-binding proposal [...]

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

03/03/2025 - 22:45

SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close. FibroGen will also conduct a [...]

Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum

03/03/2025 - 22:48

MELBOURNE, Australia and INDIANAPOLIS, March 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) invites investors to join a webinar showcasing the Company’s late-stage [...]

Merus annonce les résultats financiers de son quatrième trimestre et de l’ensemble de son exercice 2024, et fait le point sur ses activités

02/03/2025 - 02:00

- Inclusion en cours pour les études d’enregistrement de phase III visant l’évaluation du pétosemtamab en association avec le pembrolizumab en traitement de 1ᵉ ligne pour un CETC r/m PD-L1 et l’évaluation du [...]

Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

02/03/2025 - 22:13

Conference call and webcast at 8:00 a.m. ET on Monday, March 3, 2025 THE WOODLANDS, Texas, March 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will hold a [...]

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

28/02/2025 - 23:00

LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a [...]

Premier Health Reports 2025 First Quarter Results

28/02/2025 - 23:01

MONTRÉAL, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA ) (the “ Corporation ”), a leading Canadian Healthtech company, announces it has filed its unaudited Quarterly Consolidated Financial [...]

Prime Biome Reviews: Massive Breakthrough in Skin Problems, Premature Aging and Gut Health

01/03/2025 - 04:06

ST. PETERSBURG, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- In recent months, a new supplement called Prime Biome has been making waves in the health and wellness industry. Positioned as a gut and skin support formula, it [...]

International Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month

01/03/2025 - 14:45

STUDIO CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Myeloma Action Month is an annual global awareness campaign that takes place every March to raise awareness and inspire action for multiple myeloma—a blood cancer [...]

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025

01/03/2025 - 18:45

- Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU - - 82% of CSU patients reported that symptoms no longer had an impact on their quality of life at Week 52 - - 60% of [...]

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

01/03/2025 - 18:45

REDWOOD CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy [...]

Spectral AI Schedules 2024 Fourth Quarter and Full Year Financial Results and Conference Call

28/02/2025 - 14:00

DALLAS, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”) , developer of the AI-driven DeepView ® System, which received Breakthrough Device Designation from the U.S. Food and [...]

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

28/02/2025 - 14:00

-- On track to report initial data from Phase 1/2 clinical trial of PM359 for p47 phox CGD in 2025 -- -- IND-enabling studies ongoing for PM577 for Wilson’s Disease; expect to file IND and/or CTA in 1H 2026 -- -- [...]

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

28/02/2025 - 14:00

BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]